Back to Search Start Over

Pharmacological enhancement of retinoid-related orphan receptor α function mitigates spinocerebellar ataxia type 3 pathology.

Authors :
Watanave, Masashi
Hoshino, Chiaki
Konno, Ayumu
Fukuzaki, Yumi
Matsuzaki, Yasunori
Ishitani, Tohru
Hirai, Hirokazu
Source :
Neurobiology of Disease. Jan2019, Vol. 121, p263-273. 11p.
Publication Year :
2019

Abstract

Abstract Cerebellar Purkinje cells (PCs) are the sole output neurons of the cerebellar cortex, and damage to PCs results in motor deficits. Spinocerebellar ataxia type 3 (SCA3, also known as Machado–Joseph disease), a hereditary neurodegenerative disease, is caused by an abnormal expansion of the polyglutamine tract in the causative ATXN3 protein. SCA3 affects a wide range of cells in the central nervous system, including those in the cerebellum. To unravel SCA3 pathology, we used adeno-associated virus serotype 9 (AAV9) vectors to express full-length ATXN3 with an abnormally expanded 89 polyglutamine stretch (ATXN3[Q89]) in cerebellar neurons of mature wild-type mice. Mice expressing ATXN3[Q89] exhibited motor impairment in a manner dependent on the viral titer. Immunohistochemistry of the cerebellum showed ubiquitinated nuclear aggregates in PCs; degeneration of PC dendrites; and a significant decrease in multiple proteins including retinoid-related orphan receptor α (RORα), a transcription factor, and type 1 metabotropic glutamate receptor (mGluR1) signaling molecules. Patch clamp analysis of ATXN3[Q89]-expressing PCs revealed marked defects in mGluR1 signaling. Notably, the emergence of behavioral, morphological, and functional defects was inhibited by a single injection of SR1078, an RORα/γ agonist. These results suggest that RORα plays a key role in mutant ATXN3-mediated aberrant phenotypes and that the pharmacological enhancement of RORα could function as a method for therapeutic intervention in SCA3. Graphical abstract Unlabelled Image Highlights • Using AAV9 vectors, we expressed full-length mutant ATXN3 in mouse cerebellum. • The treated mice showed motor deficits and reduced levels of RORα in Purkinje cell. • The Purkinje cells showed dendritic degeneration and mGluR1 signaling defects. • Injection of SR1078, an RORα/γ agonist, ameliorated aberrant phenotypes. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09699961
Volume :
121
Database :
Academic Search Index
Journal :
Neurobiology of Disease
Publication Type :
Academic Journal
Accession number :
133046828
Full Text :
https://doi.org/10.1016/j.nbd.2018.10.014